<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font18 { font-size : 18; } .font26 { font-size : 26; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">and </span>
   <span class="font26">the </span>
   <span class="font18">for </span>
   <span class="font18">treatment </span>
   <span class="font18">with </span>
   <span class="font16">patients </span>
   <span class="font15">was </span>
   <span class="font15">were </span>
   <span class="font15">boceprevir </span>
   <span class="font14">telaprevir </span>
   <span class="font13">{background </span>
   <span class="font13">;():–. </span>
   <span class="font13">The </span>
   <span class="font13">hepatitis </span>
   <span class="font12">are </span>
   <span class="font12">margin </span>
   <span class="font12">Hepatitis </span>
   <span class="font12">cost </span>
   <span class="font12">{border-style </span>
   <span class="font12">HCV </span>
   <span class="font12">SVR </span>
   <span class="font12">px;} </span>
   <span class="font12">#ffffff;} </span>
   <span class="font12">adverse </span>
   <span class="font12">data </span>
   <span class="font12">two </span>
   <span class="font12">virus </span>
   <span class="font12">per </span>
   <span class="font12">rates </span>
   <span class="font11">randomized </span>
   <span class="font11">weeks </span>
   <span class="font11">$,. </span>
   <span class="font11">Health </span>
   <span class="font11">Medicine </span>
   <span class="font11">chronic </span>
   <span class="font11">events </span>
   <span class="font11">study </span>
   <span class="font11">tolerability </span>
   <span class="font11">Peg-IFN/RBV </span>
   <span class="font11">United </span>
   <span class="font11">cirrhosis </span>
   <span class="font11">clinical </span>
   <span class="font11">due </span>
   <span class="font11">(%) </span>
   <span class="font11">Treatment </span>
   <span class="font11">associated </span>
   <span class="font11">based </span>
   <span class="font11">between </span>
   <span class="font11">comparative </span>
   <span class="font11">effectiveness </span>
   <span class="font11">vs. </span>
   <span class="font11">when </span>
   <span class="font11">Clinical </span>
   <span class="font11">have </span>
   <span class="font11">pathogens </span>
   <span class="font11">severe </span>
   <span class="font11">these </span>
   <span class="font11">Research </span>
   <span class="font11">Sciences </span>
   <span class="font11">Therapy </span>
   <span class="font11">care </span>
   <span class="font11">from </span>
   <span class="font11">medicine. </span>
   <span class="font11">not </span>
   <span class="font11">ribavirin </span>
   <span class="font11">sciences </span>
   <span class="font11">telaprevir. </span>
   <span class="font11">States </span>
   <span class="font11">Viral </span>
   <span class="font11">combination </span>
   <span class="font11">compared </span>
   <span class="font11">controlled </span>
   <span class="font11">costs </span>
   <span class="font11">cure </span>
   <span class="font11">infection </span>
   <span class="font11">patient </span>
   <span class="font11">px; </span>
   <span class="font11">use </span>
   <span class="font11">{font-family </span>
   <span class="font10">./NEJMoa </span>
   <span class="font10">Drug </span>
   <span class="font10">Medical </span>
   <span class="font10">Patients </span>
   <span class="font10">Protease </span>
   <span class="font10">Telaprevir </span>
   <span class="font10">acquisition </span>
   <span class="font10">antiviral </span>
   <span class="font10">discontinuation </span>
   <span class="font10">drug </span>
   <span class="font10">drugs </span>
   <span class="font10">font-size </span>
   <span class="font10">leading </span>
   <span class="font10">received </span>
   <span class="font10">such </span>
   <span class="font10">trial </span>
   <span class="font10">(%)] </span>
   <span class="font10">Adverse </span>
   <span class="font10">Biology </span>
   <span class="font10">Boceprevir </span>
   <span class="font10">CONSORT </span>
   <span class="font10">Med. </span>
   <span class="font10">Randomized </span>
   <span class="font10">This </span>
   <span class="font10">Veterans </span>
   <span class="font10">YFY </span>
   <span class="font10">also </span>
   <span class="font10">can </span>
   <span class="font10">criteria </span>
   <span class="font10">differences </span>
   <span class="font10">double; </span>
   <span class="font10">experienced </span>
   <span class="font10">formulary </span>
   <span class="font10">generation </span>
   <span class="font10">group </span>
   <span class="font10">journal </span>
   <span class="font10">life </span>
   <span class="font10">newer </span>
   <span class="font10">outpatient </span>
   <span class="font10">response </span>
   <span class="font10">than </span>
   <span class="font10">therapy </span>
   <span class="font10">using </span>
   <span class="font10">veterans </span>
   <span class="font10">viral </span>
   <span class="font10">which </span>
   <span class="font10">Administration </span>
   <span class="font10">Affairs </span>
   <span class="font10">Antiviral </span>
   <span class="font10">Cleveland </span>
   <span class="font10">Controlled </span>
   <span class="font10">Engl </span>
   <span class="font10">Food </span>
   <span class="font10">RCTs </span>
   <span class="font10">additional </span>
   <span class="font10">after </span>
   <span class="font10">approved </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">both </span>
   <span class="font10">early </span>
   <span class="font10">either </span>
   <span class="font10">genotype </span>
   <span class="font10">health </span>
   <span class="font10">high </span>
   <span class="font10">higher </span>
   <span class="font10">important </span>
   <span class="font10">infection. </span>
   <span class="font10">information </span>
   <span class="font10">internal </span>
   <span class="font10">made </span>
   <span class="font10">more </span>
   <span class="font10">our </span>
   <span class="font10">pragmatic </span>
   <span class="font10">risk </span>
   <span class="font10">significantly </span>
   <span class="font10">solid; </span>
   <span class="font10">standard </span>
   <span class="font10">trials </span>
   <span class="font10">untreated </span>
   <span class="font10">who </span>
   <span class="font10">without </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">./journal.pone..tTable </span>
   <span class="font10">AEs </span>
   <span class="font10">All </span>
   <span class="font10">Annals </span>
   <span class="font10">Cleveland, </span>
   <span class="font10">Cost </span>
   <span class="font10">DAA </span>
   <span class="font10">DAAs </span>
   <span class="font10">DDA </span>
   <span class="font10">Data </span>
   <span class="font10">England </span>
   <span class="font10">Flaviviruses </span>
   <span class="font10">Hepacivirus: </span>
   <span class="font10">Inhibitor </span>
   <span class="font10">Liver </span>
   <span class="font10">Louis </span>
   <span class="font10">Methods </span>
   <span class="font10">Microbial </span>
   <span class="font10">New </span>
   <span class="font10">Ohio, </span>
   <span class="font10">Pragmatic </span>
   <span class="font10">RCT </span>
   <span class="font10">Stokes </span>
   <span class="font10">Study </span>
   <span class="font10">Total </span>
   <span class="font10">Virus </span>
   <span class="font10">access </span>
   <span class="font10">achieved </span>
   <span class="font10">adjudication </span>
   <span class="font10">and/or </span>
   <span class="font10">approval </span>
   <span class="font10">available </span>
   <span class="font10">been </span>
   <span class="font10">bold </span>
   <span class="font10">cirrhosis. </span>
   <span class="font10">courier; </span>
   <span class="font10">dasabuvir </span>
   <span class="font10">duration </span>
   <span class="font10">effect </span>
   <span class="font10">efficacy </span>
   <span class="font10">em; </span>
   <span class="font10">group, </span>
   <span class="font10">had </span>
   <span class="font10">interferon </span>
   <span class="font10">liver </span>
   <span class="font10">may </span>
   <span class="font10">naïve </span>
   <span class="font10">plus </span>
   <span class="font10">primary </span>
   <span class="font10">provide </span>
   <span class="font10">pt;} </span>
   <span class="font10">rate </span>
   <span class="font10">related </span>
   <span class="font10">required </span>
   <span class="font10">routine </span>
   <span class="font10">sample </span>
   <span class="font10">selection </span>
   <span class="font10">side </span>
   <span class="font10">sofosbuvir </span>
   <span class="font10">that </span>
   <span class="font10">their </span>
   <span class="font10">this </span>
   <span class="font10">treated </span>
   <span class="font10">treatment. </span>
   <span class="font10">trial. </span>
   <span class="font10">triple </span>
   <span class="font10">used </span>
   <span class="font10">virologic </span>
   <span class="font10">visits </span>
   <span class="font10">weeks. </span>
  </p>
 </body>
</html>
